ISRG is trading near its 200‑day moving average with a bullish MACD crossover and still delivers double‑digit revenue growth, supporting its 33x forward earnings multiple. The balance sheet remains strong, giving the upside potential to retest the $460‑$470 range.

Despite a 25% YTD decline, market sentiment appears overly negative as investors focus on short‑term valuation pain rather than the secular growth of robotic surgery. The narrative shift toward med‑tech resilience should rekindle buying interest.

Long‑term risks include valuation compression and regulatory scrutiny, but ISRG’s expanding procedure portfolio and recurring services revenue model underpin a multi‑year growth runway. The upside remains compelling for patient, long‑term holders.

Technical indicators show an RSI around 28 (oversold) and a bullish flag pattern forming on daily volume, suggesting a near‑term price bounce. The breakout above $420 would confirm the next leg toward $460.